Biosimilars: The New Era of Drug Development?

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Biosimilars: The New Era of Drug Development?

The biopharmaceutical industry has come a long way since the United States Food and Drug Administration (FDA) approval of the first biopharmaceutical (biologic) product insulin in 1982. In 2012, five of the top ten selling prescription drugs were biopharmaceuticals. Biopharmaceutical products have provided novel treatment modalities for life-threatening and rare diseases. In recent years, pharmaceutical companies are ramping up on their development of biosimilars because many patents on biological products are expiring and this enables them to earn profits from the biopharmaceutical market. Biosimilars are expected to offer competition to some of the most expensive drugs on the pharmaceutical market. Biosimilars are defined as a highly similar form of innovator’s biological products and are produced after the patent protections of such innovator biological products have expired. Biosimilars are also known as follow-on biologicals, similar biologics, and similar biotherapeutic product or subsequent-entry biologics.

Citation: Soluade KO, Do DP (2013) Biosimilars: The New Era of Drug Development? J Bioequiv Availab 5:e40. doi: 10.4172/jbb.10000e40

  • Share this page
  • Facebook
  • Twitter
  • LinkedIn
  • Google+
  • Pinterest
  • Blogger